China Journal of Chinese Materia Medica, the 1st in the field of TCM, is supervised by China Association for Science and Technology and sponsored by Institute of Chinese Pharmaceutical Association. The journal is China's earliest comprehensive core journal of traditional Chinese medicine, and always maintains the circulation top in the professional areas. The journal publishes the latest research and progress of traditional Chinese medicine and takes a leading position in numbers of articles published, downloads and citations among all journals in this discipline.
Its scope covers new achievements, technologies, methods, experiences and concepts resulting from the research on Chinese materia medica pursuant to Chinese medical and pharmaceutical theories, traditional experiences, and modern science and technology, including medicinal resources and identification, cultivation, processing, preparation, chemistry, pharmacology, theory of Chinese pharmacy and clinical practice, bencaological study.
The journal is included in CA, JST and CSCD.
Honorary Editor-in-Chief Xiao Peigen Editor-in-Chief Wang Yongyan
Associate Editors Zhang Boli, Hu Zhibi, Yao Xinsheng, Li Lianda, Li Dapeng, Yang Baofeng, Zhou Chaofan, Huang Luqi, Chen Shilin, Li He.
Executive Editorial Board Cai Shaoqing, Chen Shilin
To study the chemical constituents from the rhizome of
Menispermum dauricum, fifteen compounds,
N-methylcorydaldine (
1), thalifoline (
2), stepholidine (
3), acutumine (
4), daurisoline (
5), acutumidine (
6), dauricicoline (
7), bianfugecine (
8), 6-
O-demethylmenisporphine (
9), bianfugedine (
10), dauricoside (
11), eleutheroside D (
12), aristolactone (
13), aristoloterpenateⅠ (
14) and aristolochic acid (
15) were isolated from 75% ethanol extract of
M. dauricum by using thin layer chromatography and column chromatography methods. Their structures were identified based on their physicochemical properties and spectral data. Among them, compounds
12–1
5 were obtained from the genus Menispermum for the first time. Six alkaloids with higher contents were determined for their anti-hypoxic activities by using MTT method. As a result, six alkaloids exhibited significant anti-hypoxia activities.
This study aimed to systematically evaluate the efficacy and safety of breviscapine injection in the treatment of diabetic nephropathy (DN). Eight electronic databases and Clinical Trials.gov were searched to collect randomized controlled trials (RCTs) on breviscapine injection in the treatment of DN. According to the Cochrane Handbook 5.1, two independent reviewers screened out the literatures, extracted data and assessed the quality of the studies included. Rev Man 5.3 software was used for the data analysis. A total of 29 studies containing 37 trials were included, involving 2 097 patients, 1 054 cases in test groups and 1 043 cases in control groups. The clinical studies included had a low overall quality. According to Meta-analysis: ① Conventional therapy plus breviscapine injection was superior to conventional therapy in improving total efficiency rate, 24 h UTP, SCR, BUN, UEAR, ALB and mALB of DN at stage Ⅲ (RR total effective rate = 1.60, 95%CI [1.32, 1.93],
P < 0.000 01; SMD24 h UTP = −1.21, 95%CI [−1.56, −0.87],
P < 0.000 01; MDSCR = −6.33, 95%CI [−9.20, −3.46],
P < 0.000 1; MDBUN = −6.6, 95%CI [−1.10, −0.22],
P = 0.003; MDUEAR = −20.30, 95%CI [−28.14, −12.46],
P < 0.000 01; MDALB = 0.47, 95%CI [0.42, 0.52],
P < 0.000 01; MDmALB = −10.03, 95%CI [−10.62, −9.46],
P < 0.000 01). ② Conventional therapy plus breviscapine injection was better than conventional therapy in improving the total efficiency rate ( only one study), 24 h UTP, SCR and BUN of DN at stage Ⅳ ( RR total effective rate = 1.57, 95% CI [1.10, 2.25],
P = 0.01; SMD24 h UTP = −0.52, 95% CI [−0.71, −0.33],
P < 0.000 01; MDSCR = −35.38, 95%CI [−48.57, −22.19],
P < 0.000 01; MDBUN = −1.89, 95%CI [−3.01, −0.77],
P < 0.000 01). ③ Conventional therapy plus breviscapine injection was better than conventional therapy in improving SCR ( MD = −26.35, 95% CI [−47.45, −5.24],
P = 0.01), but no significant difference was noticed in 24 h UTP, BUN and ALB of DN at stage Ⅴ. ④ It was impossible to obtain the specific judgment information on the adverse reactions of breviscapine injection in the treatment of the disease from the existing evidences. The current evidences suggest that the combination of breviscapine injection and conventional therapy had a certain curative effect in the treatment of DN, especially that at stages Ⅲ and Ⅳ. The safety of breviscapine injection needs to be further explored. Because the low quality of the study impacted the accuracy of the result, more rigorous, high-quality, multi-center, randomized double-blind controlled trials are required to increase the support of the evidences in the future.
The paper studies and compares the metabolic difference of active ingredients of lipid-lowering flavonoid extract of from
C. aurantium L.
Var daidai Tanaka fruit in rat livers and intestinal microsomes, in order to explore the phase Ⅰ metabolism characteristics of active ingredients in livers and intestines. UPLC-MS/MS was used to establish a quantitative analysis method for active ingredients, neohesperidin and naringin, in a phase Ⅰ metabolism incubation system of liver and intestinal microsomes. Differential centrifugation was used to make liver and intestinal microsomes of rats. A phase Ⅰ metabolism incubation system was established, and the concentrations of the residual at different incubation time points were analyzed. Graphs were plotted to calculate the metabolic elimination half-life of the main active parts, with the natural logarithm residual percentage values ln (
X) at different time points as the y axis, and time t as the x axis. The metabolism characteristics of the active ingredients were compared. The established UPLC-MS/MS quantitative analysis method has a good specialization, standard curve and linear range, accuracy and precision, with a satisfactory lower quantitative limit. The method allows quantitative detection of the active ingredients in a phase Ⅰ metabolism incubation system of liver and intestinal microsomes of rats. In the rats liver microsomes incubation system, the metabolic elimination half-life of neohesperidin and naringin were (2.20 ± 0.28) h and (1.97 ± 0.28) h, respectively. The elimination half-life of neohesperidin was larger than that of naringin, with no statistically significant difference. In the rats intestinal microsomes incubation system, the metabolic elimination half-lives of neohesperidin and naringin were (3.6 8 ± 0.54) h and ( 2.26 ± 0.13) h, respectively. The elimination half-life of neohesperidin was larger than that of naringin, with statistically significant differences (
P < 0.05). The elimination half-lives of the active ingredients in liver microsomes were smaller than those in intestinal microsomes. The experiment results showed that the active ingredients of lipid-lowering flavonoid extract from
C. aurantium L.
Var daidai Tanaka fruit had different elimination half-lives in phase Ⅰ rats liver and intestinal microsomes incubation system. This implied that they had different metabolic characteristics in rats liver and intestine, and liver might be the main metabolism site of the active ingredients. The phase Ⅰ metabolism of naringin was stronger than that of neohesperidin. The differences between their metabolic characteristics might be related to the binding sites of B-ring hydroxyl in flavonoid glycosides and the number of methoxyl group. The results provided an important experimental basis for further development and clinical application of lipid-lowering flavonoid extract preparation from
C. aurantium L.
Var daidai Tanaka fruit.
To mine and discover the active components of “Coptidis Rhizome–Magnoliae Officinalis Cortex (C & M)” based on the network pharmacology, integrate and analyze the potential targets and mechanisms. The TCMSP database was used to screen active ingredients. TTD and Drug Bank databases were used to predict the potential targets by referring to relevant literature, and the pathway annotation technology was used to enrich and analyze the active ingredients and potential targets of “C & M”. A total of 29 potential target active ingredients were screened from “C & M”, including 12 alkaloids components such as (R)-canadine, berberine, coptisine, and palmatine; 3 lignans consisting of magnolol, honokiol and obovatol; 6 volatile oils consisting of
α-eudesmol,
β-eudesmol, eucalyptol and so on, and flavonoids including quercetin and neohesperidin. Corresponding 199 predicted targets were screened out, mainly including PTGS2, PTGS1, NCOA2, Hsp90 AB1, and so on. 72 signaling pathways were involved, 8 of which were related to cancer, such as prostate cancer, bladder cancer, and pancreatic cancer; 9 of which were related to endocrine, including oxytocin signaling pathway, insulin signaling pathway, thyroid hormone signaling pathway and so on, as well as inflammation-related pathway. This study has preliminarily mined and discovered the main active components and potential targets of “C & M”, providing material source for the study on the preparation of structural components of TCM.
